Showing results (151-160 of 166) with videos related to

Sort By:
Pageof 17
JAMA|September 28, 2023
Eplontersen for Hereditary Transthyretin Amyloidosis With PolyneuropathyTeresa Coelho, Wilson Marques, Noel R Dasgupta, et al.
Journal of the American Heart Association|November 12, 2025
Cardiac Resynchronization Therapy, Remodeling, and Outcome in Patients With Amyloid Transthyretin CardiomyopathyAlberto Aimo, Martina Nesti, Giuseppe Vergaro, et al.
JAMA Cardiology|November 8, 2025
Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label ExtensionKevin M Alexander, Margot K Davis, Olakunle Akinboboye, et al.
The New England Journal of Medicine|May 13, 2024
Aficamten for Symptomatic Obstructive Hypertrophic CardiomyopathyMartin S Maron, Ahmad Masri, Michael E Nassif, et al.
The New England Journal of Medicine|September 1, 2025
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic CardiomyopathyPablo Garcia-Pavia, Martin S Maron, Ahmad Masri, et al.
Journal of the American College of Cardiology|December 5, 2025
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM TrialAndrew Wang, Pablo Garcia-Pavia, Ahmad Masri, et al.
Journal of the American College of Cardiology|September 11, 2025
Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCMSheila M Hegde, Xiaowen Wang, Pablo Garcia-Pavia, et al.
JAMA Cardiology|June 17, 2026
Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical TrialGregory D Lewis, Pablo Garcia-Pavia, Ahmad Masri, et al.
Journal of the American College of Cardiology|October 1, 2024
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMMartin S Maron, Ahmad Masri, Michael E Nassif, et al.
Journal of the American Heart Association|July 26, 2024
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCaroline J Coats, Ahmad Masri, Michael E Nassif, et al.
Pageof 17